

ASX Announcement

By e-lodgement

9 September 2015

Appointment of Head of U.S. Investment Banking entity iQ Capital LLC

iQ3Corp Ltd (ASX:iQ3) is pleased to announce the appointment of Mr. David Batista to head up the investment banking operations of its U.S. subsidiary, iQ Capital LLC, based in New York.

David has over 20 years of diversified capital markets experience as an investment banker and trader. Importantly, he has demonstrable U.S./ Australian cross-border experience in capital raising, strategic advisory and financial advisory.

He has a Bachelor of Science in Business Administration and a Certificate in International Marketing from C.W. Post College. He is also FINRA Series 7, 24, 55, 63, 79 and 99 registered.

iQ3Corp's CEO, Dr. George Syrmalis, says "iQ3Corp welcomes David to our global team. It will be a pleasure to work with David at this strategic point where insight meets execution; where life science research translates into tangible, life changing technologies."

David's core mandate is to create a model investment bank that will address the unique financial needs of the emerging global life science sector and, in particular, the needs of early stage biotechnology companies.

Through David's leadership of the investment banking entity, iQ Capital LLC, iQ3Corp seeks to lead the investment community, practitioners and observers in establishing the biotech industry as the most critical asset option within the alternative asset class.

David is building a best-in-class team of people that will enable our investment banking entity, iQ Capital LLC, to engage in:

Debt or equity offerings through public or private placement

- > Pricing of securities in the debt and equity offerings
- > Origination, which deals with equity capital markets and debt capital markets
- > Underwriting
- > Marketing
- > Structuring
- > Syndication

Tel: +61 2 8239 5400

Fax: +61 2 8362 9547

info@iq3corp.com



> Managing the allocation and stabilisation activities of offerings

Mergers, acquisitions and financial restructuring

- > Tender offers
- > Selling assets
- > Corporate reorganisation or divestitures
- > Transactions involving business combinations, which might include rendering opinions solvency and fairness opinions

General Broker Dealer activities

David's unique experience in the U.S., European and Australian capital markets, together with his understanding of the cross-border investment dynamics across these regions, provide the foundations for iQ3Corp to expand its capital market distribution network into the U.S.

Media Contact

Angela Maher
Director - Marketing, Media & Communications

Tel: +61 2 8239 5407 Mob: +61 438 519 916

angela.maher@theiqgroup.com.au

About iQ3Corp:

Translating science into capital and beyond iQ3Corp is the world's first dedicated life science corporate finance and advisory firm.

About iQ Capital:

Investing in the medicines of the future

iQ Capital is a dedicated life science investment bank, physically creating the bridge between investors and the biopharma industry.

Disclaimer

Subject to any continuing obligations under the laws of the Commonwealth of Australia or the ASX listing rules, iQ3Corp Ltd (iQ3Corp or the Company) disclaims any perceived intent or undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise. Expressions such as 'believe', 'expect', 'anticipate', 'indicate', 'contemplate', 'target', 'plan', 'intends', 'continue', 'budget', 'estimate', 'may', 'will', 'schedule' and similar expressions identify forward-looking statements. The following cautionary statements qualify all forward-looking statements made in this announcement. In particular, the direction and strategies adopted by iQ3Corp and detailed in this announcement represents the Company's strategic planning and decision-making practices and are

iQ3Corp. Ltd ABN: 63 160 238 282 iQ3corp.com Level 6 222 Clarence Street Sydney NSW 2000

Tel: +61 2 8239 5400 Fax: +61 2 8362 9547 info@iq3corp.com



based on current expectations. iQ3Corp's business is subject to uncertainties, risks and contingencies, many of which are outside the control of, and are presently unknown to the Company, and could cause the actual conduct, results, performance or achievements of iQ3Corp to vary in a material way from those expressed or implied in this announcement. Investors are cautioned that forward-looking statements are not guarantees of future performance or outcomes, and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Additional information concerning iQ3Corp's business, its associated risks and operations can be found in its periodic announcements to ASX.

Tel: +61 2 8239 5400

Fax: +61 2 8362 9547

info@iq3corp.com